Advertisement
DYN vs RCKT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and RCKT is a StrongBuy.
DYN in +14.17% Uptrend, advancing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DYN advanced for three days, in 240 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DYN's RSI Indicator exited the oversold zone, 25 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 54 cases where DYN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DYN as a result. In 61 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for DYN just turned positive on October 01, 2026. Looking at past instances where DYN's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for DYN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.274) is normal, around the industry mean (2.988). P/E Ratio (-4.929) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. DYN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for RCKT crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.655) is normal, around the industry mean (2.988). P/E Ratio (-13.750) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DYN | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 92 | |
PRICE GROWTH RATING 1..100 | 73 | 85 | |
P/E GROWTH RATING 1..100 | 15 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for DYN (46) in the Electric Utilities industry. This means that RCKT’s stock grew somewhat faster than DYN’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYN (100) in the Electric Utilities industry. This means that RCKT’s stock grew similarly to DYN’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as DYN (98) in the Electric Utilities industry. This means that RCKT’s stock grew similarly to DYN’s over the last 12 months.
DYN's Price Growth Rating (73) in the Electric Utilities industry is in the same range as RCKT (85) in the Biotechnology industry. This means that DYN’s stock grew similarly to RCKT’s over the last 12 months.
RCKT's P/E Growth Rating (14) in the Biotechnology industry is in the same range as DYN (15) in the Electric Utilities industry. This means that RCKT’s stock grew similarly to DYN’s over the last 12 months.
| DYN | RCKT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 79% | N/A |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 85% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 85% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DYN’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- DYN’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DYN’s TA Score shows that 6 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).
- DYN’s TA Score: 6 bullish, 2 bearish.
- RCKT’s TA Score: 5 bullish, 3 bearish.
Price Growth
DYN (@Biotechnology) experienced а +6.85% price change this week, while RCKT (@Biotechnology) price change was -0.45% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
DYN is expected to report earnings on Nov 04, 2026.
RCKT is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EIDO | 10.53 | 0.23 | +2.23% |
| iShares MSCI Indonesia ETF (EIDO) | |||
| HYS | 89.69 | 0.14 | +0.16% |
| PIMCO 0-5 Year High Yield Corporate Bond Index Exchange-Traded Fund (HYS) | |||
| USLN | 49.89 | 0.01 | +0.03% |
| iShares Broad USD Floating Rate Loan ETF (USLN) | |||
| HALX | 25.66 | N/A | N/A |
| Tuttle Capital Heavy Assets Low Obsolescence ETF (HALX) | |||
| TRUC | 25.05 | -0.25 | -0.98% |
| VanEck Communication Services TruSector ETF (TRUC) | |||